Masimo (MASI)

Executive Summary

Masimo Corporation is a global leader in non-invasive patient monitoring technologies, renowned for its Signal Extraction Technology (SET®) pulse oximetry. The company has expanded from hospital-based monitoring into home care and consumer health, with products like the Masimo W1 health watch. Despite strong fundamentals, Masimo faces headwinds from patent litigation with Apple over pulse oximetry technology, which has weighed on its stock. The company continues to innovate, with recent FDA clearances for new sensors and a focus on expanding its rainbow® parameter platform. Masimo's financial performance remains solid, driven by recurring sensor revenue and hospital adoption. However, the Apple litigation outcome and market share shifts in the consumer wearables segment pose risks. The company's long-term growth prospects hinge on successful diversification beyond traditional pulse oximetry and resolution of legal uncertainties.

Upcoming Catalysts (preview)

• Q3 2026Resolution of Apple Patent Dispute (Settlement or Court Ruling)60% success
• Q4 2026FDA Clearance for Next-Generation Home Monitoring Platform80% success
• Q3 2026Q2 2026 Earnings Beat & Raised Guidance65% success